Study #2022-0466
An open-label phase 1 study to evaluate the safety and efficacy of AB-1015 in patients with platinum-resistant epithelia ovarian cancer
MD Anderson Study Status
Not Accepting
Treatment Agent
AB-1015
Description
This is a multi-center, open-label phase 1 dose escalation trial that uses a modified 3+3 design to identify a recommended phase 2 dose (RP2D) of AB-1015 cell product. Backfill cohorts will enroll additional subjects at doses deemed to be safe for a total enrollment of up to 12 subjects per each backfill cohort on the protocol.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Carcinoma, Ovarian Epithelial, Ovarian Neoplasms, Fallopian Tube Neoplasms, Peritoneal Neoplasms, Neoplasms, Glandular and Epithelial, Ovarian Diseases, Genital Neoplasm, Female, Abdominal Neoplasm, Recurrence
Study phase:
Phase I
Physician name:
Samer Srour
Department:
Stem Cell Transplantation
For general questions about clinical trials:
1-855-981-0775
Help #EndCancer
Give Now
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.